Search
Research
Screening for rheumatic heart disease: current approaches and controversiesIn endemic areas, RHD has long been a target of screening programmes that, historically, have relied on cardiac auscultation.
People
Catherine HalkonCatherine Halkon CH MIM END RHD Program Manager 0466 408 209 catherine.halkon@telethonkids.org.au Catherine is Program Manager across the END RHD
Research
Evaluation of safety and immunogenicity of a group a streptococcus vaccine candidate (mj8vax) in a randomized clinical trialIntramuscular administration of novel acetylated peptide-protein conjugate vaccine candidate MJ8VAX was demonstrated to be safe and immunogenic
Research
Rheumatic heart disease in pregnancy: How can health services adapt to the needs of Indigenous women? A qualitative studyHealth systems did not meet the needs of pregnant Aboriginal women with rheumatic heart disease
Research
Adherence to secondary prophylaxis for rheumatic heart disease is underestimated by register data.Adequate resources are needed for maintenance of data quality in acute rheumatic fever/ rheumatic heart disease registers to ensure provision of evidence-based care and accurate assessment of program impact.
Research
The rationale for action to end new cases of rheumatic heart disease in AustraliaThe choice of RHD is telling: the disease is a marker of inequality, a novel lens for considering health systems and a feasible target for disease control.
Research
Rheumatic heart disease: infectious disease origin, chronic care approach.Rheumatic heart disease (RHD) is a chronic cardiac condition with an infectious aetiology, causing high disease burden in low-income settings.
Research
Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveysDirect and indirect effects on pneumococcal carriage post-PCV10 are likely to result in reductions in pneumococcal disease, including in infants too young to be vaccinated
Research
An economic case for a vaccine to prevent group A streptococcus skin infectionsA vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability
Research
Primary prevention of rheumatic fever in the 21st century: evaluation of a national programmePopulation-based primary prevention of ARF through sore throat management may be effective in well-resourced settings like New Zealand